On days 14–42, and on average:

·         With hormonal therapy alone, 43 infants in 100 had spasms and 57 did not

·         With hormonal therapy plus vigabatrin, 28 infants in 100 had spasms and 72 did not


Thanks Andy! The key words being "on average’ because of course it isn’t possible to say in advance whether an individual child will be better with one treatment or the other, or be helped with neither, or whether one, or both treatments may make things worse or even harm that individual. We do seem to be seeing a collective recognition that there is a huge difference between decision making for an individual and the evidence for a population. Both are needed of course, but the population-based evidence can only inform individual decision making, and does not dictate a policy to be applied to everyone, everywhere, all of the time. Modern decision making in medicine is steadily progressing towards consultations being a skilled, nuanced negotiation involving but not dominated by information - which is itself necessarily balanced by its validity and relevance (themselves involving some careful judgements).

Great example Rohini. Thank you for posting. 

Best to all

Neal
Neal Maskrey
Visiting Professor of Evidence-informed decision making, Keele University
ADVOCATE Field Studies, University of Amsterdam; a Horizon 2020 European Oral Health Project  www.advocateoralhealth.com
Mobile: 07976276919











On 14 Jun 2018, at 13:18, Andy Hutchinson <[log in to unmask]> wrote:

On days 14–42, and on average:
·         With hormonal therapy alone, 43 infants in 100 had spasms and 57 did not
·         With hormonal therapy plus vigabatrin, 28 infants in 100 had spasms and 72 did not



To unsubscribe from the EVIDENCE-BASED-HEALTH list, click the following link:
https://www.jiscmail.ac.uk/cgi-bin/webadmin?SUBED1=EVIDENCE-BASED-HEALTH&A=1